triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial retatrutide nash trial Triple hormone

SKU: 35306117505

Pay in 4 interest-free payments of $5.90 Learn more

Live Spec

retatrutide nash trial Triple hormone receptor agonist for metabolic dysfunction associated steatotic liver disease: a randomized phase 2a Retatrutide produces up to 30.3% Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more: https: go.lilly.com msrz1v Retatrutide is a triple agonist drug targeting GLP 1, GIP, and glucagon receptors to suppress appetite and boost thermogenesis. Phase 2 trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing retatrutide investigational drug triple hormone receptor agonist Retatrutide vs Tirzepatide Compared

Store: www.cleversources.com · Domain: www.cleversources.com